FDA Commissioner nominee Scott Gottlieb has overcome opioids policy, conflict of interest and other concerns to reach the final confirmation stage.
The Senate invoked cloture on the Gottlieb nomination May 8 with a 57-41 vote, which sets an end to debate and assures confirmation